Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| WST | 8-K | bullish | 7/10 | West Pharmaceutical Services reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted | Jul 23, 2026 |
| IXHL | 8-K | neutral | 4/10 | Incannex Healthcare announced commencement of participant screening in its DReAMzz Phase 2 dose confirmation study of IH | Jul 23, 2026 |
| IKT | 8-K | bullish | 6/10 | Inhibikase Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its lead candidate IKT-001 for t | Jul 23, 2026 |
| CNTN | 8-K | bullish | 5/10 | Canton Strategic Holdings sold its clinical-stage biotech subsidiary Gravitas Life Sciences, LLC to a buyer affiliated w | Jul 23, 2026 |
| ESPR | 15-12G | neutral | 5/10 | Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effective immediately. Th | Jul 23, 2026 |
| GRML | 8-K | neutral | 4/10 | Greenland Mines Ltd adopted a limited-duration stockholder rights plan (poison pill) effective July 22, 2026, issuing on | Jul 23, 2026 |
| GRML | CLUSTER | bullish | 7/10 | Three insiders at Greenland Mines Ltd (GRML), including CFO Jeff LeBlanc, purchased $326K in open-market shares over a 7 | Jul 23, 2026 |
| INDV | PRESS-RELEASE | neutral | 1/10 | Indivior Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jul 23, 2026 |
| IXHL | PRESS-RELEASE | bullish | 6/10 | Incannex Healthcare announced that participant screening has commenced in its DReAMzz Phase 2 dose confirmation study fo | Jul 23, 2026 |
| WST | PRESS-RELEASE | bullish | 7/10 | West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating co | Jul 23, 2026 |
| SER | PRESS-RELEASE | mixed | 5/10 | Serina Therapeutics completed enrollment in Cohort 1 of its Phase 1b registrational trial for SER-252 (Parkinson's disea | Jul 23, 2026 |
| SGMT | CLUSTER | neutral | 4/10 | Three Sagimet insiders, including the CEO, sold a combined $719K in open-market sales over a 7-day window. The CEO's $49 | Jul 23, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | A minor insider selling cluster at UTHR, CEO Rothblatt and EVP/GC Mahon sold a combined $521K in open-market transaction | Jul 23, 2026 |
| ARGX | PRESS-RELEASE | neutral | 5/10 | { "summary": "argenx reported Q2 2026 diluted EPS of $7.32, beating the $6.13 consensus by 19.4%, with product net sales | Jul 23, 2026 |
| LQDA | CLUSTER | bearish | 5/10 | A massive insider selling cluster at Liquidia Corp (LQDA) saw 10 insiders, including the CEO, CFO, and CCO, sell a total | Jul 22, 2026 |
| JSPR | 3 | neutral | 3/10 | Matthew E. Ros filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his position as Chie | Jul 22, 2026 |
| KROS | 8-K | neutral | 3/10 | CFO Keith Regnante resigned effective August 3, 2026, to pursue other opportunities. Corporate Controller Annita Tanini | Jul 22, 2026 |
| CRVS | 8-K | neutral | 2/10 | Director Ian T. Clark resigned from the board of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years | Jul 22, 2026 |
| SER | 8-K | neutral | 2/10 | Serina Therapeutics appointed Farrell Simon, Pharm.D., to its Board of Directors, effective July 22, 2026. Dr. Simon, cu | Jul 22, 2026 |
| NVO | COURT-RULING | neutral | 1/10 | The District Court of New Jersey granted a joint motion to seal claim construction briefs and related exhibits in the pa | Jul 22, 2026 |
| ZSQR | 8-K | bullish | 6/10 | Z Squared Inc. terminated its $300M ATM sales agreement and $50M committed equity forward purchase agreement, both of wh | Jul 22, 2026 |
| SCLX | 8-K | mixed | 5/10 | Scilex Holding Co. completed the sale of its Vivasor preferred shares back to Vivasor for ~$12M, payable in five tranche | Jul 22, 2026 |
| CPHI | 8-K | neutral | 4/10 | China Pharma Holdings priced a registered direct offering of 2.5 million shares at $2.00 per share for gross proceeds of | Jul 22, 2026 |
| SAFX | 8-K | bearish | 6/10 | XCF Global (SAFX) entered into a $1M warrant purchase agreement with GL PART SPV II for an initial warrant to purchase 6 | Jul 22, 2026 |
| KALA | 424B5 | bearish | 8/10 | KALA BIO filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $250,000,000 in common | Jul 22, 2026 |
| SUPN | PRESS-RELEASE | neutral | 1/10 | Supernus Pharmaceuticals, Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jul 22, 2026 |
| SUPN | 8-K | neutral | 2/10 | Supernus Pharmaceuticals filed an 8-K on July 22, 2026, solely to announce the date of its Q2 2026 earnings release and | Jul 22, 2026 |
| RDY | 6-K | bearish | 6/10 | Dr. Reddy's Q1 FY2027 results were sharply below prior year: revenue fell 6% YoY to Rs.80,705M, operating profit collaps | Jul 22, 2026 |
| CHRS | PRESS-RELEASE | neutral | 1/10 | Coherus Oncology, Inc. announced it will report its Q2 2026 results on August 5, 2026. | Jul 22, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK announced FDA approval of Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, a | Jul 22, 2026 |